Overview:

CRISPR (clustered regularly interspaced short palindromic repeats) and their CRISPR-associated (Cas) proteins constitute the adaptive immune system in bacteria (1-2). This system has been leveraged to create an exemplary genome editing tool with applications in both basic research and therapeutics development (3). Cas12 and Cas13 are recognized as ideal candidates for future management of diseases such as cancer (4). Several CRISPR-Cas12 based SARS-CoV-2 detection assays have been developed (5).

Accession Number:

A0A5S8WF58

Formulation:

Recombinant protein stored in 50mM sodium phosphate, pH 7.5, 300mM NaCl, 150mM imidazole, 1mM DTT and 10% glycerol.

References:

1. Horvath, P., et al. CRISPR/Cas, the immune system of bacteria and archaea. Science, 327(5962):167-170.

2. Morange, M. What history tells us XXXVII. CRISPR-Cas: The discovery of an immune system in prokaryotes. J. Biosci. 40(2):221-223.

3. Gier, R.A., et al. 2020. High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening. Nat. Commun. 11(1):1-9.

4. Singh, M., et al. 2022. The era of Cas12 and Cas13 CRISPR-based disease diagnosis. Critical Reviews in Microbiology, DOI: 10.1080/1040841X.2021.2025041.

5. Broughton JP, et al. 2020. Rapid detection of 2019 novel coronavirus SARS-CoV-2 using a CRISPR-based DETECTR lateral flow assay. medRxiv doi: https://doi.org/10.1101/ 2020.03.06.20032334.